Medexus Pharmaceuticals (TSE:MDP) Given New C$6.00 Price Target at Stifel Nicolaus

Medexus Pharmaceuticals (TSE:MDP - Get Free Report) had its price target increased by investment analysts at Stifel Nicolaus from C$4.50 to C$6.00 in a research note issued on Thursday,BayStreet.CA reports. Stifel Nicolaus' price objective would suggest a potential upside of 58.31% from the company's previous close.

MDP has been the subject of several other research reports. Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a "strong-buy" rating in a research report on Monday, December 23rd. Leede Financial upgraded Medexus Pharmaceuticals from a "moderate buy" rating to a "strong-buy" rating in a report on Wednesday, January 22nd. Ventum Cap Mkts raised Medexus Pharmaceuticals to a "strong-buy" rating in a research note on Friday, January 17th. Finally, Raymond James raised shares of Medexus Pharmaceuticals from an "outperform" rating to a "strong-buy" rating and set a C$4.00 price objective on the stock in a research note on Wednesday, January 8th. Two equities research analysts have rated the stock with a buy rating and five have assigned a strong buy rating to the stock. According to MarketBeat.com, Medexus Pharmaceuticals presently has an average rating of "Strong Buy" and an average target price of C$6.13.

Medexus Pharmaceuticals Stock Down 1.6 %

MDP stock traded down C$0.06 during midday trading on Thursday, reaching C$3.79. The stock had a trading volume of 57,940 shares, compared to its average volume of 189,994. The firm has a market cap of C$92.97 million, a price-to-earnings ratio of 75.80 and a beta of 1.96. Medexus Pharmaceuticals has a twelve month low of C$1.47 and a twelve month high of C$5.56. The business has a fifty day simple moving average of C$3.44 and a two-hundred day simple moving average of C$2.78.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.